{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:48:04Z","timestamp":1789984084698,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Slovenian Research Agency research program","award":["P1-0170"],"award-info":[{"award-number":["P1-0170"]}]},{"name":"the Slovenian Research Agency research program","award":["P3-0308"],"award-info":[{"award-number":["P3-0308"]}]},{"name":"University Medical Centre Ljubljana","award":["20240051"],"award-info":[{"award-number":["20240051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02398-6","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:08:55Z","timestamp":1740503335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial"],"prefix":"10.1186","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct04613167","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-192X","authenticated-orcid":false,"given":"Andreja","family":"Rehberger Likozar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Levstek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Karun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Trebu\u0161ak Podkraj\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Zupan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miran","family":"\u0160ebe\u0161tjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"18","key":"2398_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"2398_CR2","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"5","key":"2398_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","volume":"78","author":"GG Schwartz","year":"2021","unstructured":"Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, et al. Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol. J Am Coll Cardiol. 2021;78(5):421\u201333.","journal-title":"J Am Coll Cardiol"},{"key":"2398_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fgene.2017.00189","volume":"8","author":"P Naeli","year":"2017","unstructured":"Naeli P, Mirzadeh Azad F, Malakootian M, Seidah NG, Mowla SJ. Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224. Front Genet. 2017;8:189.","journal-title":"Front Genet"},{"key":"2398_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fcvm.2020.00081","volume":"7","author":"AG Salerno","year":"2020","unstructured":"Salerno AG, van Solingen C, Scotti E, Wanschel ACBA, Afonso MS, Oldebeken SR, et al. LDL receptor pathway regulation by miR-224 and miR-520d. Front Cardiovasc Med. 2020;7:81.","journal-title":"Front Cardiovasc Med"},{"key":"2398_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154768","volume":"119","author":"X Xu","year":"2021","unstructured":"Xu X, Dong Y, Ma N, Kong W, Yu C, Gong L, et al. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice. Metabolism. 2021;119: 154768.","journal-title":"Metabolism"},{"issue":"23","key":"2398_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143812","volume":"5","author":"J Dong","year":"2020","unstructured":"Dong J, He M, Li J, Pessentheiner A, Wang C, Zhang J, et al. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight. 2020;5(23): e143812.","journal-title":"JCI Insight."},{"issue":"705","key":"2398_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2021.108916","volume":"15","author":"C Zhai","year":"2021","unstructured":"Zhai C, Sun Y, Qian G, Pan H, Xie S, Sun Z, et al. LncRNA AK087124\/miR-224-5p\/PTEN axis modulates endothelial cell injury in atherosclerosis through apoptosis and AKT signaling pathway. Arch Biochem Biophys. 2021;15(705): 108916.","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"2398_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13105-022-00871-y","volume":"78","author":"Q Peng","year":"2022","unstructured":"Peng Q, Yin R, Zhu X, Jin L, Wang J, Pan X, et al. miR-155 activates the NLRP3 inflammasome by regulating the MEK\/ERK\/NF-\u03baB pathway in carotid atherosclerotic plaques in ApoE\u2212\/\u2212 mice. J Physiol Biochem. 2022;78(2):365\u201375.","journal-title":"J Physiol Biochem"},{"key":"2398_CR10","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.3389\/bjbs.2022.10592","volume":"79","author":"D Li","year":"2022","unstructured":"Li D, Pan J. Diagnostic and prognostic value analysis of miR-206 in asymptomatic carotid artery stenosis. Br J Biomed Sci. 2022;79:10592.","journal-title":"Br J Biomed Sci"},{"key":"2398_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.athplu.2022.07.001","volume":"50","author":"A Rehberger Likozar","year":"2022","unstructured":"Rehberger Likozar A, \u0160ebe\u0161tjen M. Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels. Atheroscler Plus. 2022;50:1\u20139.","journal-title":"Atheroscler Plus"},{"issue":"3","key":"2398_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","volume":"12","author":"G Maulucci","year":"2018","unstructured":"Maulucci G, Cipriani F, Russo D, Casavecchia G, Di Staso C, Di Martino L, et al. Improved endothelial function after short-term therapy with evolocumab. J Clin Lipidol. 2018;12(3):669\u201373.","journal-title":"J Clin Lipidol"},{"key":"2398_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","volume":"194","author":"A Di Minno","year":"2020","unstructured":"Di Minno A, Gentile M, Iannuzzo G, Calcaterra I, Tripaldella M, Porro B, et al. Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy. Thromb Res. 2020;194:229\u201336.","journal-title":"Thromb Res"},{"issue":"3","key":"2398_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/genes14030632","volume":"14","author":"T Levstek","year":"2023","unstructured":"Levstek T, Karun T, Rehberger Likozar A, \u0160ebe\u0161tjen M, Trebu\u0161ak PK. Interplay between microRNAs, serum proprotein convertase subtilisin\/kexin type 9 (PCSK9), and lipid parameters in patients with very high lipoprotein(a) treated with PCSK9 inhibitors. Genes. 2023;14(3):632.","journal-title":"Genes"},{"issue":"11","key":"2398_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.5551\/jat.57562","volume":"28","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Uematsu M, Horikoshi T, Yoshizaki T, Kobayashi T, Saito Y, et al. Improvement in brachial endothelial vasomotor function and brachial-ankle pulse wave velocity reduces the residual risk for cardiovascular events after optimal medical treatment in patients with coronary artery disease. J Atheroscler Thromb. 2021;28(11):1133\u201344.","journal-title":"J Atheroscler Thromb"},{"issue":"34","key":"2398_CR16","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"963","key":"2398_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176232","volume":"15","author":"A Rehberger Likozar","year":"2024","unstructured":"Rehberger Likozar A, Ugov\u0161ek S, \u0160ebe\u0161tjen M. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients. Eur J Pharmacol. 2024;15(963): 176232.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2398_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"7","key":"2398_CR19","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/biom11070962","volume":"11","author":"AV Zhelankin","year":"2021","unstructured":"Zhelankin AV, Stonogina DA, Vasiliev SV, Babalyan KA, Sharova EI, Doludin YV, et al. Circulating extracellular miRNA analysis in patients with stable CAD and acute coronary syndromes. Biomolecules. 2021;11(7):962.","journal-title":"Biomolecules"},{"issue":"4","key":"2398_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods (San Diego Calif). 2001;25(4):402\u20138.","journal-title":"Methods (San Diego Calif)"},{"issue":"12","key":"2398_CR21","first-page":"181","volume":"8","author":"A Rehberger Likozar","year":"2021","unstructured":"Rehberger Likozar A, Blinc A, Trebu\u0161ak Podkraj\u0161ek K, \u0160ebe\u0161tjen M. LPA genotypes and haplotypes are associated with lipoprotein(a) levels but not arterial wall properties in stable post-coronary event patients with very high lipoprotein(a) levels. J Cardiovasc Dev Dis. 2021;8(12):181.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"4","key":"2398_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u201360.","journal-title":"Behav Res Methods"},{"issue":"3","key":"2398_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/antiox12030578","volume":"12","author":"A Silla","year":"2023","unstructured":"Silla A, Fogacci F, Punzo A, Hrelia S, Simoni P, Caliceti C, et al. Treatment with PCSK9 inhibitor evolocumab improves vascular oxidative stress and arterial stiffness in hypercholesterolemic patients with high cardiovascular risk. Antioxid Basel Switz. 2023;12(3):578.","journal-title":"Antioxid Basel Switz"},{"issue":"9","key":"2398_CR24","doi-asserted-by":"publisher","first-page":"BSR20201885","DOI":"10.1042\/BSR20201885","volume":"40","author":"HJ Lin","year":"2020","unstructured":"Lin HJ, Yu SL, Su TC, Hsu HC, Chen MF, Lee YT, et al. Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia. Biosci Rep. 2020;40(9):BSR20201885.","journal-title":"Biosci Rep"},{"issue":"11","key":"2398_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206974","volume":"13","author":"W Gallo","year":"2018","unstructured":"Gallo W, Esguerra JLS, Eliasson L, Melander O. miR-483-5p associates with obesity and insulin resistance and independently associates with new onset diabetes mellitus and cardiovascular disease. PLoS ONE. 2018;13(11): e0206974.","journal-title":"PLoS ONE"},{"issue":"1","key":"2398_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/CIRCRESAHA.114.300645","volume":"114","author":"KJ Rayner","year":"2014","unstructured":"Rayner KJ, Moore KJ. MicroRNA control of high-density lipoprotein metabolism and function. Circ Res. 2014;114(1):183\u201392.","journal-title":"Circ Res"},{"issue":"6","key":"2398_CR27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/ATVBAHA.116.307028","volume":"36","author":"A Canfr\u00e1n-Duque","year":"2016","unstructured":"Canfr\u00e1n-Duque A, Lin CS, Goedeke L, Su\u00e1rez Y, Fern\u00e1ndez-Hernando C. Micro-RNAs and high-density lipoprotein metabolism. Arterioscler Thromb Vasc Biol. 2016;36(6):1076\u201384.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2398_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12872-021-01964-0","volume":"21","author":"W Gallo","year":"2021","unstructured":"Gallo W, Ottosson F, Kennb\u00e4ck C, Jujic A, Esguerra JLS, Eliasson L, et al. Replication study reveals miR-483-5p as an important target in prevention of cardiometabolic disease. BMC Cardiovasc Disord. 2021;21(1):162.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"2398_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","volume":"135","author":"G Reyes-Soffer","year":"2017","unstructured":"Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135(4):352\u201362.","journal-title":"Circulation"},{"issue":"27","key":"2398_CR30","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","volume":"39","author":"GF Watts","year":"2018","unstructured":"Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018;39(27):2577\u201385.","journal-title":"Eur Heart J"},{"issue":"1","key":"2398_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12872-022-02756-w","volume":"22","author":"K James","year":"2022","unstructured":"James K, Bryl-Gorecka P, Olde B, Gidlof O, Torngren K, Erlinge D. Increased expression of miR-224-5p in circulating extracellular vesicles of patients with reduced coronary flow reserve. BMC Cardiovasc Disord. 2022;22(1):321.","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"2398_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1357-2725(97)00128-3","volume":"30","author":"DA Clark","year":"1998","unstructured":"Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol. 1998;30(3):293\u20138.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"2398_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCRESAHA.117.310610","volume":"120","author":"N Wang","year":"2017","unstructured":"Wang N, Tall AR. A new approach to PCSK9 therapeutics. Circ Res. 2017;120(7):1063\u20135.","journal-title":"Circ Res"},{"issue":"5","key":"2398_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jacl.2020.07.009","volume":"14","author":"EM Roth","year":"2020","unstructured":"Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, et al. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. J Clin Lipidol. 2020;14(5):707\u201319.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2398_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/biomedicines10010193","volume":"10","author":"T Metzner","year":"2022","unstructured":"Metzner T, Leitner DR, Mellitzer K, Beck A, Sourij H, Stojakovic T, et al. Effects of alirocumab on triglyceride metabolism: a fat-tolerance test and nuclear magnetic resonance spectroscopy study. Biomedicines. 2022;10(1):193.","journal-title":"Biomedicines"},{"issue":"2","key":"2398_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/apha.14272","volume":"241","author":"G Liu","year":"2025","unstructured":"Liu G, Yu X, Cui C, Li X, Wang T, Palade PT, et al. The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism. Acta Physiol. 2025;241(2): e14272.","journal-title":"Acta Physiol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02398-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:09:01Z","timestamp":1740503341000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02398-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02398-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures performed in this study that involved human patients were carried out in accordance with the ethical guidelines of the 1964 Declaration of Helsinki. Approval for this study was obtained from the National Medical Ethics Committee of the Republic of Slovenia (reference number: KME 0120-357\/2018\/8). The study is registered with CinicalTrials under the number NCT04613167. The initial aim was to include at least 70 patients to achieve the desired power of the study. However, we managed to include even more patients (N\u2009=\u200995) and to collect the samples for the current analysis. All patients signed a written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}